University of Wollongong

Research Online
Faculty of Science, Medicine and Health Papers: part A

Faculty of Science, Medicine and Health

January 2015

Aβ-dependent
A -dependent reduction of NCAM2-mediated synaptic adhesion
contributes to synapse loss in Alzheimer's disease
Iryna Leshchyns'Ka
University of New South Wales

Heng Tai Liew
University of New South Wales

Claire E. Shepherd
Neuroscience Research Australia

Glenda M. Halliday
Neuroscience Research Australia

Claire H. Stevens
University of New South Wales, stevensc@uow.edu.au

See next page for additional authors

Follow this and additional works at: https://ro.uow.edu.au/smhpapers

Recommended Citation
Leshchyns'Ka, Iryna; Liew, Heng Tai; Shepherd, Claire E.; Halliday, Glenda M.; Stevens, Claire H.; Ke, Yazi D.;
Ittner, Lars M.; and Sytnyk, Vladimir, "Aβ-dependent reduction of NCAM2-mediated synaptic adhesion
contributes to synapse loss in Alzheimer's disease" (2015). Faculty of Science, Medicine and Health Papers: part A. 3809.
https://ro.uow.edu.au/smhpapers/3809

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Aβ-dependent
A -dependent reduction of NCAM2-mediated synaptic adhesion contributes to
synapse loss in Alzheimer's disease
Abstract
Alzheimer's disease (AD) is characterized by synapse loss due to mechanisms that remain poorly
understood. We show that the neural cell adhesion molecule 2 (NCAM2) is enriched in synapses in the
human hippocampus. This enrichment is abolished in the hippocampus of AD patients and in brains of
mice overexpressing the human amyloid-β (Aβ) precursor protein carrying the pathogenic Swedish
mutation. Aβ binds to NCAM2 at the cell surface of cultured hippocampal neurons and induces removal
of NCAM2 from synapses. In AD hippocampus, cleavage of the membrane proximal external region of
NCAM2 is increased and soluble extracellular fragments of NCAM2 (NCAM2-ED) accumulate.
Knockdown of NCAM2 expression or incubation with NCAM2-ED induces disassembly of
GluR1-containing glutamatergic synapses in cultured hippocampal neurons. Aβ-dependent disassembly
of GluR1-containing synapses is inhibited in neurons overexpressing a cleavage-resistant mutant of
NCAM2. Our data indicate that Aβ-dependent disruption of NCAM2 functions in AD hippocampus
contributes to synapse loss.
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Ab-dependent reduction of NCAM2-mediated
synaptic adhesion contributes to synapse loss
in Alzheimer’s disease
Iryna Leshchyns’ka1, Heng Tai Liew1, Claire Shepherd2, Glenda M. Halliday2, Claire H. Stevens2,3, Yazi D. Ke3,
Lars M. Ittner2,3 & Vladimir Sytnyk1

Alzheimer’s disease (AD) is characterized by synapse loss due to mechanisms that remain
poorly understood. We show that the neural cell adhesion molecule 2 (NCAM2) is enriched
in synapses in the human hippocampus. This enrichment is abolished in the hippocampus of
AD patients and in brains of mice overexpressing the human amyloid-b (Ab) precursor
protein carrying the pathogenic Swedish mutation. Ab binds to NCAM2 at the cell surface of
cultured hippocampal neurons and induces removal of NCAM2 from synapses. In AD
hippocampus, cleavage of the membrane proximal external region of NCAM2 is increased
and soluble extracellular fragments of NCAM2 (NCAM2-ED) accumulate. Knockdown of
NCAM2 expression or incubation with NCAM2-ED induces disassembly of GluR1-containing
glutamatergic synapses in cultured hippocampal neurons. Ab-dependent disassembly of
GluR1-containing synapses is inhibited in neurons overexpressing a cleavage-resistant mutant
of NCAM2. Our data indicate that Ab-dependent disruption of NCAM2 functions in AD
hippocampus contributes to synapse loss.
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L

earning and memory processes depend on the number and
correct functioning of synapses in the brain. Cell adhesion
molecules are enriched in the pre- and postsynaptic
membranes. These molecules physically connect synaptic membranes, providing mechanical stabilization of synaptic contacts1–3,
are necessary for the formation of new synapses during neuronal
development4,5, and maintain and regulate synaptic plasticity in
adults6–10.
Alzheimer’s disease (AD) is a neurodegenerative brain
condition predominantly of the aging population. One of the
earliest signs of AD is the loss of synapses11, which can at least
partially be linked to the toxicity mediated by Ab12–14, a peptide
that accumulates in the brains of AD patients. The impact of AD
on synaptic adhesion and the role of synaptic cell adhesion
molecules in the progression of the disease remains poorly
understood.
The neural cell adhesion molecule 2 (NCAM2), sometimes
designated OCAM, belongs to the immunoglobulin superfamily
of cell adhesion molecules. NCAM2 participates in homophilic
trans-interactions15,16. During human embryonic development,
NCAM2 is expressed in several tissues, including lung, liver, and
kidney with the highest expression in the brain17. The expression
level of NCAM2 peaks around postnatal day 21 and remains high
during adulthood15, suggesting that the protein is necessary both
during development and in adult brains. Accordingly, studies
with cultured neurons and in NCAM2 deﬁcient mice show that
NCAM2 is important for the development of the brain, and the
olfactory system in particular18,19.
The NCAM2 gene is located on chromosome 21 in humans
and NCAM2 overexpression has been suggested to be one of the
factors contributing to the symptoms of Down syndrome17,
which presents with early-onset AD pathology. Single-nucleotide
polymorphisms in the NCAM2 gene have been reported as a risk
factor related to the progression of AD in the Japanese
population20. A recent genome-wide association study has
found an association between single-nucleotide polymorphisms
in the NCAM2 gene and levels of Ab in the cerebrospinal ﬂuid in
humans, suggesting that NCAM2 is involved in the pathogenic
pathway to the senile plaques that concentrate in AD brains21.
Since genetic association studies indicate a link between NCAM2
and AD, we have analysed whether AD pathology inﬂuences
levels of NCAM2 in synapses. Our results indicate that the
synaptic adhesion mediated by NCAM2 is highly susceptible to
Ab toxicity and that proteolytic fragments of NCAM2 generated
in an Ab-dependent manner can directly contribute to the
induction of synapse disassembly.
Results
Synaptic NCAM2 is reduced in the hippocampus in AD. To
analyse whether functions of NCAM2 are affected in AD, frozen
post-mortem brain tissue of AD patients and non-affected controls (n ¼ 10 each) was analysed by western blot with antibodies
against NCAM2. The detailed demographic data for the subjects
analysed are presented in Supplementary Table 1. Total levels of
NCAM2 were slightly increased in the hippocampus, but not
signiﬁcantly affected in the cerebellum or superior temporal
cortex in AD (Supplementary Fig. 1). In contrast, levels of
VGLUT1, a presynaptic marker-protein of excitatory synapses,
were reduced in AD hippocampus (Supplementary Fig. 1), indicating a loss of excitatory synapses. Levels of VGAT, a presynaptic marker-protein of inhibitory synapses, were not
signiﬁcantly affected in any brain region analysed (Supplementary Fig. 1).
Changes in the protein levels in brain homogenates do not
necessarily reﬂect changes in the protein levels in synapses. To
2

analyse whether the synaptic function of NCAM2 is affected in
AD, we compared the enrichment of NCAM2 in synaptosomes
isolated from the brain tissue of individuals with AD and nonaffected controls by western blot analysis of synaptosomes and
total homogenates of the brains used for synaptosome preparations. Equal total protein amounts from each probe were applied
to the gels to compensate for any possible differences in the yield
of synaptosomes because of the synapse loss observed in AD.
Western blot analysis with antibodies against actin, VGLUT1,
VGAT, synaptophysin (a general presynaptic marker-protein),
and PSD95 (a postsynaptic marker-protein), showed that these
proteins were enriched to similar levels in synaptosomes from AD
and control brains, indicating similar purities of intact synaptosome isolations (Fig. 1a). Western blot analysis showed that in
control individuals NCAM2 was highly enriched in synaptosomes
from the hippocampus and to a lower degree in synaptosomes
from the temporal cortex and cerebellum (Fig. 1a,b). This
synaptic enrichment of NCAM2 was signiﬁcantly reduced in
synaptosomes from AD hippocampi (Fig. 1a,b). The synaptic
enrichment of NCAM2 was slightly lower in the AD versus
control cerebellum, however the difference was not statistically
signiﬁcant (Fig. 1a,b).
NCAM2 is a membrane protein (Fig. 2a). Its proteolysis results
in the release of the free, non-membrane-attached soluble
fragments22. To investigate whether a reduction in the synaptic
levels of NCAM2 is accompanied by changes in NCAM2
proteolysis, soluble protein fractions were isolated from the
cerebellum, superior temporal cortex and hippocampus of control
and AD brains. Western blot analysis of these fractions showed
enrichment of the soluble marker-protein GAPDH as well as
NCAM2-positive bands (Fig. 1c), which were detected at a lower
molecular weight compared with NCAM2-positive bands in
synaptosomes (Fig. 1c). Since the antibodies used in our analysis
were against the extracellular domain of NCAM2 (NCAM2-ED),
the B100-kDa NCAM2 fragment detectable in the soluble
protein fractions likely represented NCAM2-ED. In agreement,
the molecular weight of recombinant NCAM2-ED was also
B100 kDa (Fig. 3a).
The levels of the soluble NCAM2 fragments relative to the
NCAM2 levels in synaptosomes were signiﬁcantly increased in
AD hippocampus (Fig. 1c,d). Similar results were obtained when
the levels of NCAM2 in the soluble protein fraction were
normalized to the levels of GAPDH (Fig. 1e). The levels of the
soluble NCAM2 were not statistically signiﬁcantly different in the
temporal cortex and cerebellum in AD brains (Fig. 1c–e). These
results suggested increased proteolysis of NCAM2 and release of
NCAM2-ED from the synaptic plasma membrane in the
hippocampus in AD brains.
Cleavage of NCAM2aa682-701 is increased in AD brains. To
conﬁrm that amino acid sequences within NCAM2, which are
proximal to the extracellular leaﬂet of the membrane, can be
cleaved in the brain tissue, peptides corresponding to the amino
acid sequences within this region of NCAM2 (Fig. 2a) were
analysed in a cleavage assay (Fig. 2b). In this assay, peptides
labelled with FITC and biotin at the N- and C-terminus,
respectively, were incubated with lysates of homogenates or
synaptosomes from control or AD hippocampus. Non-cleaved
peptides were removed using streptavidin beads. Levels of FITC
groups released by the peptide cleavage were analysed by measuring FITC ﬂuorescence (Fig. 2b). This analysis showed that the
release of FITC groups from the most membrane proximal
NCAM2aa682-701 fragment was signiﬁcantly higher than from
the adjacent NCAM2aa666-685 fragment (Fig. 2c), indicating that
this sequence is susceptible to cleavage. Cleavage efﬁciency of
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Figure 1 | Synaptic accumulation of NCAM2 is reduced in the hippocampus of AD-affected individuals. (a) Western blot analysis of homogenates
and synaptosomes prepared using brain tissue from cerebellum, temporal cortex and hippocampus of control and AD individuals. Note enrichment of
synaptophysin, PSD95, actin, VGLUT and VGAT in synaptosomes indicating efﬁcient synaptosome isolation. NCAM2 is highly enriched in synaptosomes
versus homogenates from the hippocampus in control but not in AD individuals. Full-length versions of the western blots are shown in Supplementary
Figs 6 and 7. (b) Graphs show the ratio of the respective protein levels in synaptosomes to homogenates for individual cases and mean±s.e.m.
(n ¼ 10 control and n ¼ 10 AD cases were analysed). *P ¼ 0.0039, Mann–Whitney test. (c) Western blot analysis of the soluble protein fractions and
synaptosomes prepared using brain tissue from the cerebellum, temporal cortex and hippocampus of control and AD individuals. Total protein
concentration in synaptosomes was kept at 25% of that in the soluble protein fraction to improve visualization of the protein bands in both fractions on one
blot. Probes were analysed with antibodies against the extracellular domain of NCAM2 and GAPDH, which served as a loading control. Note increased
levels of soluble B100-kDa NCAM2 fragments in the soluble protein fraction from the hippocampus and temporal cortex of the AD individuals. Full-length
versions of the western blots are shown in Supplementary Fig. 8. (d,e) Graphs show NCAM2 levels in the soluble protein fraction normalized to NCAM2
levels in synaptosomes (d) and NCAM2 levels in the soluble protein fraction normalized to GAPDH levels in homogenates (e) for individual cases and
mean±s.e.m. (n ¼ 10 control and n ¼ 10 AD cases were analysed). *Po0.05, Mann–Whitney test.
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Figure 2 | Cleavage of the membrane-adjacent extracellular fragment of NCAM2 is increased in AD brains. (a) Diagram showing the structure of
NCAM2. Ig, immunoglobulin-like domain; Fn, ﬁbronectin type III domain. Peptides used in the cleavage assay and corresponding to aa682-701
(NCAM2aa682-701) and aa666-685 (NCAM2aa666-685) of human NCAM2 are shown below. Asparagine 689 and aspartic acid 693 exchanged to
alanine in the cleavage assay shown in c are highlighted in bold. (b) Scheme of the peptide cleavage assay. Peptides labelled with FITC and biotin at the
N- and C-terminus, respectively, were incubated either with the total brain lysate or lysate of synaptosomes. Non-cleaved peptides and biotin-containing
fragments of the cleaved peptides were removed using streptavidin-coated beads. The remaining FITC ﬂuorescence was used as an estimate of peptide
cleavage. (c) Graphs show the efﬁciency of the peptide cleavage (mean þ s.e.m.) with the ﬂuorescence signals for NCAM2aa682-701 in controls set to
100%. Lysates from eight controls and eight AD patients were analysed. Note that the efﬁciency of NCAM2aa682-701 cleavage is higher in AD cases and
particularly in synaptosomes. NCAM2aa682-701 cleavage is reduced by mutating aspartic acid 693. *Po0.05 (compared as indicated), ^Po0.05
(compared with NCAM2aa682-701 cleavage in AD) analysis of variance with Tukey’s multiple comparisons test.

NCAM2aa682-701 was markedly increased in AD samples with
the strongest effect observed in the lysates of synaptosomes when
compared with the total homogenate lysate (Fig. 2c). Cleavage of
NCAM2aa682-701 was reduced when aspartic acid 693 was
changed to alanine, but not after mutating asparagine 689 to
alanine (Fig. 2c). Thus, we found that the extracellular region of
NCAM2 is cleaved at amino acids 685–701, with aspartic acid at
position 693 being essential. Furthermore, the cleavage rate at this
site is increased in synapses of AD hippocampus.
NCAM2 binds to Ab in vitro. In search for possible mechanisms
of the increased proteolysis of synaptic NCAM2 in AD, we
determined whether puriﬁed recombinant NCAM2-ED (Fig. 3a)
binds to Ab1-42 in vitro using ELISA. Ab1-42 bound to NCAM2-ED
immobilized on plastic in a concentration-dependent manner
4

(Fig. 3b). No binding to bovine serum albumin (BSA) used as a
negative control was observed. Hence, NCAM2 can directly
associate with Ab1-42.
To further understand the nature of the complexes formed by
NCAM2-ED and Ab1-42, the sizes of the protein particles formed
by NCAM2-ED or Ab1-42 alone or when NCAM2-ED and Ab1-42
were incubated together were measured by using dynamic light
scattering. This analysis showed that Ab1-42 formed particles with
the hydrodynamic diameter of B140 nm (Fig. 3c), as previously
reported for Ab oligomers23. In agreement, SDS–polyacrylamide
gel electrophoresis (PAGE) and western blot analysis of the Ab1-42
preparation with human Ab-speciﬁc antibodies (6E10, Covance)
showed a band at B18 kDa corresponding to Ab1-42 tetramers and
a minor band at B4.5 kDa corresponding to Ab1-42 monomers but
no higher molecular weight bands (440 kDa) corresponding to
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Figure 3 | The extracellular domain of NCAM2 binds to Ab. (a) Recombinant extracellular domains of NCAM2 (NCAM2-ED) analysed by silver staining
and western blot with antibodies against the extracellular domain of NCAM2. (b) NCAM2-ED immobilized on the plastic surface of 96-well plates was
assessed by ELISA for its ability to bind increasing concentrations of Ab1-42. Mean þ s.e.m. (n ¼ 3) OD values from a representative experiment are shown.
Note that Ab1-42 binds to NCAM2-ED but not to BSA in a concentration-dependent manner. The experiment was performed ﬁve times with the same
effect. (c) DLS analysis of the hydrodynamic diameters of the protein particles in the solutions containing Ab1-42 oligomers alone, NCAM2-ED alone or a
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of the Ab1–42 oligomer preparation used in this study. (f,g) PAGE (f) and western blot (g) analyses of the probes containing NCAM2-ED, NCAM2-ED
incubated with Ab1-42, or Ab1-42 performed under non-reducing conditions. Dashed lines and arrows indicate the position of the peaks in the labelling
density determined by the densitogram analysis. A fragment of the densitogram covering 75–150 kDa range is shown in f. Note that the density peak in
the NCAM2 band in the probes incubated with Ab1-42 is shifted to the higher molecular weight (grey arrows) when compared with the NCAM2 band
in the absence of Ab1-42 (black arrows). Full-length versions of the western blots are shown in Supplementary Fig. 9. OD, optical density. AU, arbitrary units.
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protoﬁbrils (Fig. 3e)24. The hydrodynamic diameter of the particles
formed by NCAM2-ED was B260 nm (Fig. 3c). NCAM2-ED
incubated with Ab1-42 oligomers formed larger protein particles
with the hydrodynamic diameter of B440 nm (Fig. 3c), indicating
binding of NCAM2 to Ab1-42. In contrast, incubation of Ab1-42
oligomers with BSA did not induce any shift in the size indicating
no particles were formed by BSA and Ab1-42 (Fig. 3d).
To conﬁrm the dynamic light scattering data, NCAM2-ED
incubated with or without Ab1-42 oligomers was analysed by
PAGE under non-reducing conditions. Analysis of the densitograms of the Coomassie-stained gels showed that incubation with
Ab1-42 resulted in a slight B15–20 kDa shift of the NCAM2-ED
band to the upper molecular weight with no higher molecular
complexes observed (n ¼ 3 experiments; Fig. 3f). A similar shift
was observed when the probes were analysed by western blot with
antibodies against NCAM2 (Fig. 3g). Furthermore, western blot
analysis with antibodies against Ab conﬁrmed that the shifted
band was also positive for Ab (Fig. 3g). Since the shift
corresponded to the molecular weight of the tetrameric Ab1-42
oligomers (Fig. 3e), our data indicate that Ab1-42 oligomers bind
to NCAM2.
6

To analyse whether NCAM2 can also associate with Ab1-42
oligomers at the cell surface of neurons, we used cultured mouse
hippocampal neurons. First, we conﬁrmed synaptic localization of
NCAM2 in these neurons by using immunoﬂuorescence labelling.
Labelling with antibodies against NCAM2 showed that it was
distributed along dendrites that stained for the dendritic markerprotein MAP2 (Fig. 4a). Higher magniﬁcation visualized clusters
of NCAM2 co-localizing with the presynaptic marker synaptophysin (Fig. 4b). Interestingly, NCAM2 was enriched in a subset
of synapses (Fig. 4b). Co-labelling with antibodies against the
postsynaptic marker of excitatory synapses, PSD95, showed that
NCAM2 co-localized with PSD95-positive synapses (Fig. 4c,
Pearson’s correlation coefﬁcient for NCAM2 and PSD95 labelling
was 0.752±0.008, n ¼ 23 neurons analysed). These observations
indicate that similarly to its distribution in human brain, NCAM2
is enriched in synapses of mouse hippocampal neurons.
Next, neurons were treated with 0.5 mM Ab1-42 oligomers or
equivalent volume of the neuronal culture medium used to dilute
oligomers for 30 min or 24 h. Neurons were then subjected to a
proximity ligation (PL) assay using antibodies against Ab1-42 (sc28365; Santa Cruz Biotechnology) and antibodies against the
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Figure 5 | Ab1–42 oligomers bind to NCAM2 at the cell surface of neurons. Representative images of cultured hippocampal neurons, which were either
mock-treated or incubated with Ab1-42 oligomers for 30 min or 24 h. Ab1-42/NCAM2 complexes at the cell surface were detected by PL using antibodies
against Ab1-42 and the extracellular domain of NCAM2 applied to detergent non-permeabilized neurons. Neurons were then co-labelled with antibodies
against Ab1-42 and synaptophysin used to visualize neurons. Differential interference contrast images (DIC) and inverted grey scale ﬂuorescence images
are shown. Note endogenous APP labelling in mock-treated neurons and increased levels of Ab1-42 immunoreactivity and NCAM2/Ab1-42 proximity ligation
reaction products along neurites of neurons treated with Ab1-42 oligomers for 30 min. NCAM2/Ab1-42 proximity ligation reaction products and Ab1-42
oligomers were observed along neurites and also adsorbed to the substrate around neurons treated with Ab1-42 oligomers for 24 h. A dead neuron with
disrupted morphology of the soma, fragmented dendrites and highly positive for Ab1-42 is marked with an arrow. Graphs show levels of Ab1-42 and
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(mean þ s.e.m., n450 neurons analysed in each group). Po0.05, analysis of variance with uncorrected Fisher’s least square difference test. The
experiment was performed twice with the same effect. Scale bar, 40 mm.

extracellular domain of NCAM2 (ref. 19) to detect complexes of
NCAM2 and Ab1-42. Neurons were co-labelled for synaptophysin
and Ab1-42 to visualize synapses and neuronal morphology.
Proximity ligation produced a weak reaction in mock-treated
control neurons (Fig. 5), suggesting that NCAM2 associates with
endogenous APP present in cultured hippocampal neurons (see
also Fig. 8f). Neurons incubated with Ab1-42 oligomers for 30 min

presented with a strong punctuated Ab immunoreactivity along
dendrites partially overlapping with synaptophysin accumulations (Fig. 5), indicating that Ab1-42 oligomers bound to the cell
surface at synapses, as described previously13. This was
accompanied by a signiﬁcant increase in the NCAM2/Ab1-42 PL
signal (Fig. 5). Interestingly, the NCAM2/Ab1-42 PL products
were observed not only along neurites but also on the substrate in
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neurite-free areas (Fig. 5). In neurons incubated with Ab1-42
oligomers for 24 h, levels of NCAM2/Ab1-42 ligation products
adsorbed to the substrate around neurons were increased as
compared to neurons incubated with Ab1-42 for 30 min (Fig. 5).
This increase in the substrate-bound ligation products was
accompanied by a reduction in levels of Ab1-42
immunoreactivity along neurites in neurons incubated with
Ab1-42 oligomers for 24 h as compared with neurons incubated
with Ab1-42 oligomers for 30 min (Fig. 5), suggesting that
prolonged incubation with Ab1-42 oligomers resulted in the
dissociation of NCAM2/Ab1-42 complexes from the cell surface
and subsequent adsorption to the substrate. Dead neurons
containing high levels of Ab immunoreactivity, probably
representing intracellular accumulations of Ab, were also
observed in cultures treated with Ab1-42 oligomers for 24 h
(Fig. 5), in accordance with previous reports showing that
intraneuronal accumulation of Ab1-42 precedes neuronal death25.
Omission of one of the antibodies abolished the PL signal
indicating the speciﬁcity of the reaction (Fig. 5). Taken together,
our data suggest that Ab1–42 oligomers form complexes with
NCAM2 that progressively dissociate from synaptic sites into the
medium.
Ab removes NCAM2 from synapses of hippocampal neurons.
To conﬁrm that exposure to Ab1-42 oligomers affects levels of
NCAM2 at synapses, we analysed levels of NCAM2 in synaptosomes isolated from control mock-treated cultured hippocampal
neurons and neurons treated with Ab1-42 oligomers for 24 h.
Western blot analysis of synaptosomes showed that NCAM2 was
highly enriched in synaptosomes isolated from control neurons
(Fig. 6a), in agreement with immunocytochemical analysis
(Fig. 4) and observations with human brain tissue (Fig. 1a). The
synaptic enrichment of NCAM2 was signiﬁcantly reduced in
synaptosomes from neurons treated with Ab1-42 oligomers
(Fig. 6a). Levels of synaptophysin were similar in synaptosomes
isolated from Ab1-42- and mock-treated neurons, indicating
similar isolation efﬁciency (Fig. 6a).
The fact that levels of NCAM2 were not signiﬁcantly affected
in the temporal cortex of AD-affected individuals (Fig. 1a)
prompted us to analyse the effect of Ab1-42 oligomers on NCAM2
levels in synapses of cortical neurons. Synaptosomes isolated from
cultured cortical neurons showed NCAM2 enrichment in
synapses, albeit at lower levels as compared with hippocampal
neurons (Fig. 6a). Interestingly, but in line with our ﬁndings in
human temporal cortex (Fig. 1a), levels of NCAM2 in synaptosomes were not reduced by exposure of cortical neurons to Ab1-42
for 24 h (Fig. 6a). Western blot analysis of the cell culture lysates
showed that in hippocampal and cortical neurons incubated with
Ab1-42 oligomers the overall levels of NCAM2 were increased
when compared with NCAM2 levels in mock-treated neurons
(Fig. 6a), indicating a similar compensatory reaction in both types
of neurons. It is therefore possible that cortical neurons are more
efﬁcient in compensating for the Ab-dependent loss of NCAM2
because levels of NCAM2 in synapses of these neurons are lower.
To conﬁrm that Ab1-42 induces removal of NCAM2 from the
cell surface of cultured hippocampal neurons, we compared levels
of the soluble proteolytic products of NCAM2 in the cell culture
medium collected from control mock-treated neurons and
neurons treated with Ab1-42 oligomers for 24 h. Western blot
analysis showed that levels of soluble NCAM2 with the molecular
weight of B100 kDa were signiﬁcantly increased in culture
medium from Ab1-42-treated hippocampal neurons (Fig. 6b),
further indicating that Ab1-42 induces removal of NCAM2 off the
neuronal cell surface. In contrast, levels of the soluble proteolytic
products of CHL1, another synaptic cell adhesion molecule of the
immunoglobulin superfamily26,27, were not changed in the
8

culture medium from Ab1-42-treated hippocampal neurons
(Fig. 6b). Incubation with Ab1-42 did not increase levels of
soluble NCAM2 in the culture medium from cortical neurons
(Fig. 6b), suggesting that cortical neurons are more resistant to
Ab1-42-dependent NCAM2 proteolysis.
Ab binds to and removes NCAM2 from synapses in APP23
mice. Next, we used Ab-forming human mutant APP-expressing
APP23 mice to analyse whether Ab interacts with NCAM2 in the
brain in vivo. Immunolabelling of brain slices with antibodies to
NCAM2 showed widespread NCAM2 expression in hippocampi
of both wild-type and APP23 mice of different age (Fig. 7a,
Supplementary Figs 3 and 4). Antibodies against human Ab
(6E10, Covance) stained neurons in the hippocampus of APP23
mice (Fig. 7a, Supplementary Fig. 3). NCAM2 and Ab partially
co-localized along dendrites of the neurons in 9-month-old
APP23 mice (Fig. 7d), which did not show overt plaques (Fig. 7a),
in small Ab aggregates probably representing nascent plaques in
12-month-old APP23 mice (Supplementary Figs 3 and 4), and in
small Ab aggregates and around mature plaques in 24-month-old
APP23 mice (Supplementary Figs 3 and 4). No labelling was
observed when primary antibodies were omitted (Fig. 7b,c).
To analyse whether increased levels of Ab inﬂuence synaptic
accumulation of NCAM2 in vivo, we compared synaptic
enrichment of NCAM2 in brains of APP23 mice and wild-type
littermates. Western blot analysis showed that NCAM2 was
highly enriched in synaptosomes from the hippocampus of wildtype mice in all ages tested (Fig. 8a). Enrichment of NCAM2 in
hippocampal synaptosomes was signiﬁcantly reduced in APP23
mice at all ages analysed (Fig. 8a,b). NCAM2 was also highly
enriched in synaptosomes isolated from the cortex of 5–9- and
12-month-old wild-type mice (Fig. 8a). This enrichment of
NCAM2 progressively declined in APP23 mice with the
difference reaching statistical signiﬁcance at 12 months of age
(Fig. 8a,c). Interestingly, synaptic levels of NCAM2 in the cortex
of 15-month-old wild-type mice declined to the level of APP23
mice, possibly reﬂecting ageing. Synaptic enrichment of NCAM2
in the cerebellum was not different between genotypes in mice of
all ages tested (Fig. 8a,d), consistent with absence of transgene
expression in the cerebellum of APP23 mice28. A decline in
synaptic levels of NCAM2 was accompanied by an increase in
soluble NCAM2 fragments in the hippocampus of APP23 mice
(Fig. 8e; ratio of soluble NCAM2 to full-length synaptic NCAM2
levels in synaptosomes was 0.11±0.02 in the hippocampus of
wild-type animals versus 0.24±0.05* in the hippocampus of
APP23 mice, n ¼ 5, *Po0.05, paired t-test), indicating increased
proteolysis of NCAM2.
Although co-localization data (Fig. 7) suggests that NCAM2
and Ab interact, it does not exclude that NCAM2 co-localize with
full-length APP or its fragments containing epitopes present in
Ab and recognized by 6E10 antibodies. To conﬁrm that NCAM2
interacts with Ab, co-immunoprecipitation experiments were
performed. Immunoprecipitation of NCAM2 from APP23 brain
extracts co-immunoprecipitated Ab species of B20–37 kDa
detectable with antibodies against human Ab (6E10, Covance)
(Fig. 8f). Co-immunoprecipitation efﬁciency was stronger in the
hippocampus when compared with cortex (Fig. 8f). NCAM2
immunoprecipitates from the cortex and hippocampus of APP23
mice also contained full-length APP and B75 kDa products
possibly representing APP proteolytic fragments containing
epitopes present in Ab and detectable with 6E10 antibody
(Fig. 8f). To conﬁrm that Ab1-42 associates with NCAM2,
NCAM2 immunoprecipitates were also analysed with the rabbit
monoclonal antibody (D3E10, Cell Signaling) recognizing Ab1-42,
but not full-length APP or other Ab species. Labelling with this
antibody also showed immunoreactivity at B20–37 kDa in
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NCAM2 immunoprecipitates from APP23 hippocampus (Fig. 8f).
Taken together, our results suggest that Ab binds to NCAM2
particularly in the hippocampus and may induce removal of
NCAM2 from synapses in vivo.
Disruption of NCAM2 adhesion promotes synapse disassembly. Soluble NCAM2-ED contains amino acid sequences
normally involved in mediating NCAM2-NCAM2 homophilic
adhesion16. NCAM2-ED may therefore bind to membranelocalized NCAM2 and affect its interactions and functions. Since
NCAM2-ED accumulates in AD brains (Fig. 1c–e) and is
generated in response to Ab1-42 (Fig. 6b), we determined
whether application of NCAM2-ED affects synapse integrity in
cultured hippocampal neurons. Neurons were incubated with
recombinant NCAM2-ED (2.5 mg ml  1) for 24 h or mock-treated

with equivalent volume of the neuronal culture medium used to
dilute NCAM2-ED. To visualize synapses, neurons were labelled
with antibodies against the extracellular domain of the GluR1
subunit of AMPA receptors applied before permeabilization of
membranes with detergent and co-labelled with antibodies
against synaptophysin applied after permeabilizing membranes
with detergent. Confocal microscopy analysis showed that in
mock-treated neurons over 80% of cell surface GluR1 clusters
overlapped with synaptophysin accumulations and were thus
identiﬁed as synaptic (Fig. 9a,b). The number of synaptic GluR1
clusters was signiﬁcantly reduced in neurons incubated with
NCAM2-ED (Fig. 9a,b). This reduction was accompanied by a
reduction in the numbers of synaptophysin accumulations along
dendrites and by an increase in the numbers of extra-synaptic
GluR1 clusters identiﬁed as clusters that did not overlap with
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Figure 7 | NCAM2 co-localizes with Ab1-42 in brains of APP23 transgenic mice. Low-magniﬁcation confocal images of the hippocampus (a) and highmagniﬁcation images of the CA1 region of the hippocampus (d) of 9-month-old wild-type (wt) and APP23 mice (APP23) are shown. Brain sections were
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antibodies) are shown in b,c. Scale bar ¼ 200 mm (a–c), 40 mm (d), 10 mm (d, blow-up image).

synaptophysin accumulations (Fig. 9a,b). Since NCAM2-ED can
bind not only to the membrane bound NCAM2 but possibly also
to other binding partners of NCAM2 at the cell surface, we also
analysed whether synapse integrity is affected by antibodies,
which bind speciﬁcally to the extracellular domain of NCAM2
(ref. 19, Supplementary Fig. 2). Incubation of neurons with the
antibodies against the extracellular domain of NCAM2
(2.5 mg ml  1) for 24 h also resulted in reduced density of GluR1positive synapses along dendrites (Fig. 9a,b). A similar effect was
observed in neurons incubated with Ab1-42 oligomers (0.5 mM) for
24 h (Fig. 9a,b), in agreement with previous reports13. Incubation
with NCAM2-ED, antibodies against the extracellular domain of
NCAM2 or Ab1-42 oligomers also resulted in reduced numbers of
10

synapses positive for the NR1 subunit of the NMDA receptor and
an increase in numbers of extra-synaptic NR1 clusters along
dendrites of neurons (Fig. 9c). Our observations thus indicate that
disruption of NCAM2 functions at the cell surface results in the
disassembly of glutamatergic synapses.
Since the actin cytoskeleton plays a central role in anchoring of
the receptors in the postsynaptic density, we determined whether
exposure to NCAM2-ED inﬂuences actin at synapses. In mocktreated control neurons, accumulations of F-actin visualized
with ﬂuorophore-labelled phalloidin co-localized with
synaptophysin clusters (Fig. 9d). Numbers of synaptic phalloidin
clusters and overall phalloidin intensity along dendrites were
reduced in neurons treated for 24 h with NCAM2-ED or
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Figure 8 | NCAM2 binds to Ab and its synaptic accumulation is reduced in the hippocampus of APP23 transgenic mice. (a) Western blot analysis of the
homogenates (hom.) and synaptosomes (synapt.) prepared using hippocampus, cortex and cerebellum from wild-type and APP23 transgenic (APPtg)
mice. Probes were analysed with antibodies against NCAM2 and synaptophysin used as a loading control. Note reduced synaptic enrichment of NCAM2 in
the hippocampus of APP23 transgenic mice. Full-length versions of the western blots are shown in Supplementary Fig. 11. (b–d) Graphs show synaptic
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immunoprecipitation efﬁciency. Full-length versions of the western blots are shown in Supplementary Fig. 13.

antibodies against the extracellular domain of NCAM2
(Fig. 9d,e). This effect was accompanied by the increased
appearance of non-synaptic ﬁlopodia and lamellipodia along

dendrites of neurons treated with NCAM2-ED or antibodies
against NCAM2 (Fig. 9d), resulting in an increased ratio of
dendrite area-to-length (Fig. 9e). A similar effect was observed in
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neurons treated for 24 h with Ab1-42 oligomers (Fig. 9d,e), as
described previously13.
Cleavage-resistant NCAM2 reduces Ab-dependent synapse loss.
Since Ab1-42 induces removal of NCAM2 from synapses, we
determined whether knockdown of NCAM2 expression by
transfection of neurons with targeted miRNA (NCAM2miR)
alters synapse numbers. Immunoﬂuorescence analysis of transfected neurons showed that numbers of synaptic cell surface

GluR1 clusters were reduced while numbers of extra-synaptic cell
surface GluR1 clusters were increased in neurons transfected with
NCAM2miR when compared with neurons transfected with
control miRNA (Fig. 10a,b). When neurons transfected with
control miRNA were incubated with Ab1-42 oligomers for 24 h,
numbers of synaptic GluR1 clusters declined and numbers of
extra-synaptic GluR1 clusters increased to the levels observed in
NCAM2miR transfected neurons (Fig. 10a,b). Administration of
Ab1-42 oligomers to NCAM2miR-transfected neurons did not

*

*

Aβ

100
80
60
40
20
0

*

40

*

*

30

*

20
10
Aβ

M
oc
AM k
2N
E
C
AM D
2m
Ab

0

ED

Ab

C

AM

AM
C
N

10

N

20

2m

2-

Aβ

0.0
k

*

*

0.5
oc

*

*

*

1.0

M

*

1.5

0

C

C

N

N

Labelling
50
40
30
20
10
0

*

Ab

AM

2-

ED

Aβ

Aβ

N
C

*

*

AM

oc
k

*

2m

1000
800
600
400
200
0
M

*

A
C
AM β
2E
AM D
2m
Ab
N

M

oc
k

*

N
C

Overlay

N
C

Phalloidin

Area/length

Synaptophysin

Phalloidin, AU

NCAM2-ED

NCAM2mAb

Treatment
Mock

40
30

2.0

Aβ

*

M
oc
AM k
2N
E
C
AM D
2m
Ab

*

Non-synaptic
NR1, %

*

Aβ

100
80
60
40
20
0

M
oc
AM k
2
N
-E
C
AM D
2m
Ab

Synaptic NR1, %

Aβ

Synaptophysin, μm–1

N

C

NCAM2mAb

Non-synaptic GluR1, %

N

C

NCAM2-ED

Mock

Overlay

M
oc
AM k
2N
E
C
AM D
2m
Ab

Surface GluR1

Synaptophysin

Synaptic GluR1, %

Treatment

Labelling

12

NATURE COMMUNICATIONS | 6:8836 | DOI: 10.1038/ncomms9836 | www.nature.com/naturecommunications

& 2015 Macmillan Publishers Limited. All rights reserved.

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9836

increase numbers of extra-synaptic GluR1 clusters any further
(Fig. 10a,b), indicating that the effects of NCAM2 knockdown
and Ab1-42 are not additive. Transfection with NCAM2miR did
not signiﬁcantly reduce the effect of Ab1-42 on the overall numbers of synaptophysin-positive synaptic boutons along dendrites
(Fig. 10c).
To analyse whether overexpression of NCAM2 changes the
responsiveness of neurons to Ab, neurons were transfected with
DNA coding for non-mutated human NCAM2 or cleavageresistant NCAM2 with aspartic acid 693 in the cleavage site
mutated to alanine (NCAM2D693A). Transfection with both
NCAM2 constructs resulted in expression of the NCAM2
proteins recognized with the NCAM2 antibodies at the expected
molecular weight (Supplementary Fig. 2C). In neurons transfected with non-mutated NCAM2, the percentage of nonsynaptic GluR1 clusters was increased when compared with
neurons transfected with green ﬂuorescent protein (GFP) only
(Fig. 10d), possibly due to cleavage of overexpressed NCAM2 and
therefore increased levels of NCAM2-ED, which affects numbers
of GluR1-containing synapses (Fig. 9b). In agreement, the neurite
area/length ratio was increased in NCAM2- versus GFPtransfected neurons (Fig. 10f), as observed for neurons treated
with NCAM2-ED (Fig. 9d, e). Furthermore, these effects were
blocked in neurons transfected with NCAM2D693A (Fig. 10d,f),
indicating that cleavage of NCAM2 is required. In neurons
transfected with NCAM2D693A, the Ab1-42-dependent increase
in numbers of extra-synaptic GluR1 clusters was blocked
(Fig. 10d), and Ab1-42-dependent reduction in the overall
numbers of synaptic accumulations along dendrites was partially
inhibited (Fig. 10e).
Because overexpression of non-mutated NCAM2 induced
changes obscuring the effects of Ab, we also analysed whether
responsiveness to Ab is restored in neurons, in which human
NCAM2 was expressed on the NCAM2-negative background
achieved by knockdown of expression of mouse NCAM2 using
mouse NCAM2-speciﬁc NCAM2miR. Analysis of the immunoﬂuorescence images of transfected neurons labelled with antibodies against NCAM2 showed that in neurons transfected with
NCAM2miR only the levels of NCAM2 were reduced to
25.4±2.1% of NCAM2 levels in control neurons. By testing
different concentrations of DNAs, we found that in neurons cotransfected with DNAs coding for NCAM2miR and non-mutated
human NCAM2 or human NCAM2D693A at 1:1 ratio the levels
of NCAM2 immunoﬂuorescence were increased to 72.9±5.5%
and 62.8±6.4% of the levels in control neurons, respectively. The
percentage of non-synaptic GluR1 clusters was reduced in
neurons co-transfected with NCAM2miR and non-mutated

NCAM2 or NCAM2D693A when compared with neurons
transfected with NCAM2miR only (Fig. 10g). Application of
Ab1-42 for 24 h induced an increase in the percentage of nonsynaptic GluR1 clusters (Fig. 10g) and an increase in the neurite
area/length ratio (Fig. 10h) in neurons co-transfected with nonmutated NCAM2. This effect was, however, blocked in neurons
co-transfected with NCAM2D693A (Fig. 10g,h).
Taken together, our results indicate that Ab affects the
numbers of GluR1-containing glutamatergic synapses in a
NCAM2-dependent manner.
Discussion
Alzheimer’s disease is characterized by loss of synapses, which is
the strongest correlate of cognitive decline11,29–32 and possibly
one of the earliest events in AD pathogenesis30,33. Synapses are
long lasting contacts between neurons, which are stabilized by a
number of cell adhesion molecules that concentrate in pre- and
postsynaptic membranes2,5. Cell adhesion molecules play an
essential role in maintaining synapse functionality and stability.
Although cell adhesion molecules of many families are required
for the synapse integrity8,10, elimination of even one type of
synaptic cell adhesion molecule is often sufﬁcient to induce
abnormalities in synapse ultrastructure and protein
composition6,7. In the present study, we show that levels of the
synaptic cell adhesion molecule NCAM2 are markedly reduced in
hippocampal synapses in AD brains and Ab-forming APP23
mice. Our observations that disruption of NCAM2 interactions at
the cell surface, knockdown of NCAM2 expression and Ab
exposure result in reduced numbers of glutamatergic synapses in
hippocampal neurons suggest that abnormalities in NCAM2mediated synaptic adhesion contribute to synapse loss in AD.
Although the mechanisms of synapse disassembly in AD remain
poorly understood, previous studies indicated that synapse loss can
be linked to Ab-induced toxicity12,34,35. Our observations showing
that synaptic levels of NCAM2 are similarly reduced in APP23
mice and in cultured hippocampal neurons from wild-type mice
exposed to Ab argue in favour of Ab-dependent mechanisms in
the disruption of NCAM2-mediated synaptic adhesion. We
however do not exclude that other factors, such as disrupted
trafﬁcking of NCAM2 to synapses, may also contribute to the
reduction of NCAM2 levels at synapses. Strikingly, the effects of
Ab on synaptic targeting of NCAM2 were particularly strong in
hippocampal but not cortical or cerebellar neurons. The enhanced
susceptibility of synaptic NCAM2 to Ab-dependent proteolysis
may therefore contribute to selective vulnerability of the
hippocampus to AD.

Figure 9 | Disruption of NCAM2 functions at the neuronal cell surface promotes glutamatergic synapse disassembly. (a–e) Cultured hippocampal
neurons were either mock-treated or incubated with the recombinant soluble extracellular domains of NCAM2 (NCAM2-ED), antibodies against the
extracellular domain of NCAM2 (NCAM2mAb), or Ab1-42 oligomers. In a,b, neurons were labelled with antibodies against the extracellular domain of GluR1
before permeabilization of membranes with detergent, and co-labelled with antibodies against synaptophysin after permeabilization of membranes with
detergent. Representative images of dendrites are shown (a). Note co-localization of cell surface GluR1 accumulations with synaptophysin clusters in mocktreated neurons, and increased levels of non-synaptic cell surface GluR1 accumulations in neurons treated with NCAM2-ED, NCAM2mAb or Ab1-42. Graphs
(b) show the percentage of synaptic and non-synaptic GluR1 clusters relative to total number of GluR1 clusters along dendrites and numbers of
synaptophysin accumulations per dendrite length (mean þ s.e.m.). *Po0.0001 (analysis of variance with Dunnett’s multiple comparison test, n480
dendrites from 20 neurons were analysed in each group). In c, neurons were labelled with antibodies against the extracellular domain of NR1 before
permeabilization of membranes with detergent, and co-labelled with antibodies against synaptophysin after permeabilization of membranes with detergent.
Graphs show the percentage of synaptic and non-synaptic NR1 clusters relative to total number of NR1 clusters along dendrites (mean þ s.e.m.).
*Po0.0001 (analysis of variance with Dunnett’s multiple comparison test, n485 dendrites from 20 neurons were analysed). In d,e, neurons were
co-labelled with ﬂuorescent phalloidin and synaptophysin antibodies. Representative images of dendrites are shown in d. Note higher labelling intensity and
co-localization with synaptophysin of the phalloidin-labelled polymerized actin accumulations in control neurons versus neurons treated with Ab1-42,
NCAM2-ED or NCAM2mAb. Note increased numbers of ﬁlopodia and lamellipodia in neurons treated with Ab1-42, NCAM2-ED or NCAM2 mAb. Graphs
(e) show ratio of the dendrite area-to-length and phalloidin labelling intensity of dendrites of neurons. Mean values þ s.e.m. are shown. *Po0.0001
(analysis of variance with Dunnett’s multiple comparison test, n ¼ 50 dendrites from 20 neurons were analysed in each group). Scale bar, 10 mm (in a,d).
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Figure 10 | Ab1-42 reduces the number of GluR1-containing synapses in the NCAM2-dependent manner. (a) Representative images of dendrites of
cultured hippocampal neurons transfected either with control negative miRNA (negative miR) or NCAM2miR and either mock-treated or incubated with
Ab1-42. Transfected neurons were identiﬁed by ﬂuorescence of GFP, which is co-expressed together with miRNA. Neurons were co-labelled with antibodies
against cell surface GluR1 and synaptophysin. Note that the number of synaptic GluR1 clusters is reduced and the number of non-synaptic GluR1 clusters is
increased in neurons transfected with NCAM2miR. Scale bar, 10 mm. (b,c) Graphs show mean þ s.e.m. percentage of synaptic and non-synaptic GluR1
clusters relative to the total number of GluR1 clusters along dendrites (b) and numbers of synaptophysin accumulations per dendrite length normalized to
the mean number in mock-treated neurons (c) for neurons described in (a). (d–f) Graphs show mean þ s.e.m. percentage of synaptic and non-synaptic
GluR1 clusters relative to the total number of GluR1 clusters along dendrites (d), number of synaptophysin accumulations per dendrite length normalized to
the mean number in mock-treated neurons (e), and area/length ratio (f) in cultured hippocampal neurons transfected either with GFP alone or cotransfected with GFP and non-mutated NCAM2 (NCAM2WT) or NCAM2D693A mutant and either mock-treated or incubated with Ab1-42. (g,h) Graphs
show mean þ s.e.m. percentage of non-synaptic GluR1 clusters relative to the total number of GluR1 clusters along dendrites (g) and area/length ratio (h)
in cultured hippocampal neurons co-transfected with NCAM2 miR and either GFP, non-mutated NCAM2 (WT) or NCAM2D693A mutant (D693A) and
either mock-treated or incubated with Ab1-42. In b–h, *Po0.01 (compared as indicated), ^Po0.01 (compared with mock-treated neurons transfected with
negative miR (b), GFP (d–f) or co-transfected with NCAM2miR and GFP (g–h)), analysis of variance with Tukey’s multiple comparison test, n450
dendrites from 20 neurons were analysed in each group.
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Our observations that NCAM2 directly interacts with synthetic
Ab1-42, that Ab1-42 forms a molecular complex with NCAM2 at
the neuronal cell surface and that complexes of NCAM2 and
oligomers of Ab can be isolated from APP23 mouse brains,
indicate that NCAM2 may function as a previously unrecognized
receptor for Ab at the neuronal cell surface. Previous studies have
shown that Ab can also bind to other cell adhesion molecules at
the neuronal cell surface, among which are the prion protein36
and L137. In addition, a number of cell adhesion molecules have
been shown to interact with APP, including the neural cell
adhesion molecule 1 (NCAM1)38 and TAG1 (ref. 39). It remains
to be investigated whether the NCAM2/Ab complex comprises
other adhesion molecules and cell surface proteins. Interestingly,
NCAM1, a homologue of NCAM2, binds to prion protein40 and
L1 (ref. 41). However, in spite of homology to NCAM2, NCAM1
binds to a region of APP which is different to the Ab-containing
region38.
The fact that NCAM2 directly binds to Ab suggests that this
event may predispose NCAM2 to proteolysis and shedding of its
extracellular domain. Ab-derived diffusible ligands, a form of
Ab1-42 used in our study, have been previously shown to attach to
the postsynaptic sites of excitatory synapses and induce removal
of cell surface proteins13. How exactly Ab induces NCAM2
proteolysis remains to be investigated, but interestingly, we could
show site-speciﬁc cleavage of NCAM2 is enhanced in AD
synapses. Importantly, Ab has been shown previously to inhibit
shedding of another synaptic cell adhesion molecule,
N-cadherin42, an observation which indicates that Ab does not
induce overall degradation of the synaptic cell adhesion machinery
but rather target-speciﬁc components, including NCAM2.
Notably, we found that extracellular domains of NCAM2
accumulate in brains of AD patients. In addition to enhanced
proteolysis, an increase in the levels of soluble NCAM2 may also
be related to overall increased expression of NCAM2 triggered by
exposure to Ab. A similar increase in levels of expression were
observed for cellular prion protein, another key player in Ab
toxicity36, expression of which is increased in response to
incubation with Ab43. Our observation that incubation of
cultured hippocampal neurons with recombinant extracellular
domains of NCAM2 results in a reduction of the numbers of
glutamatergic synapses suggests that proteolytic products of
NCAM2 may exacerbate the effect of Ab by interfering with
NCAM2-mediated homophilic interactions and promoting
further disassembly of synaptic contacts. In addition to
the disruption of NCAM2-mediated adhesion, binding of the
extracellular domains of NCAM2 may inﬂuence the intracellular
cytoskeleton by activating intracellular signalling, which can be
induced by other members of this family of cell adhesion
molecules in response to extracellular ligand binding44.
Taken together, we show that Ab induces synaptic loss and
proteolysis of NCAM2 in cell culture and APP transgenic mouse
models, providing a mechanistic explanation for synaptic
NCAM2 changes in AD brains. The detrimental effects of
proteolyically cleaved extracellular NCAM2 on synapses may
augment the Ab toxicity in the pathogenesis of AD. The exact
molecular mechanisms underlying Ab-induced NCAM2 changes,
and to which degree it contributes to onset and progression of
disease remains to be established. Nevertheless, our data reveal a
new role of NCAM2 in AD that warrants further investigation.
Methods
Antibodies.

Rat monoclonal antibodies against the extracellular domain of
NCAM2 (MAB778; R&D Systems) were used at 2.5 mg ml  1 for immunocytochemistry (IC) and in experiments aimed to disrupt NCAM2 functions in live
cultured hippocampal neurons. Goat polyclonal antibodies against the extracellular
domain of NCAM2 (sc-51336; Santa Cruz Biotechnology) were used at 4 mg ml  1

for IC, immunohistochemistry (IH) and in the PL assay. Mouse monoclonal
antibodies against the extracellular domain of NCAM2 (sc-136328; Santa Cruz
Biotechnology) were used for IC (2 mg ml  1), Western blot (WB, 1 mg ml  1),
immunoprecipitation (IP, 7 mg per 1 mg of total protein) and to immobilize
NCAM2 for ELISA (10 mg ml  1). Goat antibodies against the extracellular domain
of CHL1 (AF2147; R&D systems) were used for WB (1 mg ml  1); goat polyclonal
and mouse monoclonal antibodies against synaptophysin (sc-7568, sc-17750; Santa
Cruz Biotechnology) were used for WB (1 mg ml  1) and IC (4 mg ml  1); mouse
monoclonal antibodies against actin (sc-8432; Santa Cruz Biotechnology;
1 mg ml  1), VGLUT1 (sc-377425; Santa Cruz Biotechnology; 1 mg ml  1) and
VGAT (sc-393373; Santa Cruz Biotechnology; 1 mg ml  1) were used for WB;
mouse monoclonal antibodies against PSD95 (clone K28/86, Millipore) were used
for WB (0.1 mg ml  1) and IC (1 mg ml  1); mouse monoclonal antibodies against
MAP2 (M4403; Sigma; 1:100) were used for IC; mouse monoclonal antibodies
against Ab (sc-28365; Santa Cruz Biotechnology) were used for WB (1 mg ml  1),
IC (2 mg ml  1), PL (2 mg ml  1); rabbit polyclonal antibodies against Ab (prediluted Ab42 detection antibody; KHB3441 ELISA kit; Life Technologies) were
used for ELISA; human-speciﬁc mouse monoclonal antibodies against Ab (6E10)
(Covance) were used for IH (1:100) and WB (1:1,000); rabbit monoclonal antibodies against Ab1-42 (D3E10, Cell Signaling Technology; 1:200) were used for WB;
rabbit polyclonal (A5060) and mouse monoclonal antibodies against actin (Sigma)
were used for WB (1:1,000); rabbit polyclonal antibodies against the extracellular
epitope of the GluR1 subunit of AMPA receptors (AGC-004; Alomone Labs, Jerusalem, Israel) were used for IC (1:100); and rabbit polyclonal antibodies against
the extracellular epitope of the NR1 subunit of NMDA receptors (AGC-001;
Alomone Labs) were used for IC (1:100). We also used secondary antibodies
coupled to Cy2 (for IC, 1:400), Cy3 (for IC, 1:400) or Cy5 (for IC and IH, 1:400), or
horseradish peroxidase (HRP) (for WB, 1:25,000) from Jackson Immunoresearch,
and Alexa 555 coupled secondary antibodies (for IH, 1:1,000) from Life
Technologies.
Human brain tissue. Analysis of the human brain tissue was approved by the
Human Research Ethics Committee of the University of New South Wales (permit
HREC 09301). Brain tissues from ten cases per group (AD-affected individuals
versus non-affected individuals with no pathology, similar age) were obtained from
the Sydney Brain Bank. Cases met current diagnostic criteria for either AD or
neuropathological control45. Case details are given in Supplementary Table 1.
Brain tissue homogenates. Brain tissue homogenates (10%, w/v) were prepared
in HOMO-A buffer: HOMO buffer (1 mM MgCl2, 1 mM CaCl2, 1 mM NaHCO3,
5 mM Tris, pH 7.4) containing 0.32 M sucrose, EDTA-free complete inhibitors
(Roche) and 1 mM PMSF (Sigma).
Soluble protein fractions and synaptosomes from brain tissue. Homogenates
were used for synaptosome isolation as described27,46. All steps were performed at
4 °C. Brieﬂy, homogenates were centrifuged at 1,400 g for 10 min. The supernatant
and pellet were resuspended in HOMO-A buffer and centrifuged for 10 min at
700 g. The resulting supernatants were combined and centrifuged at 17,500 g for
15 min. The supernatant was centrifuged at 200,000 g for 1 h and used as the
soluble fraction. The 17,500 g pellet was resuspended in HOMO-A buffer and
applied on the top of a step gradient with interfaces of 0.65, 0.85, 1 and 1.2 M
sucrose in HOMO buffer. The 700-g pellets were combined, adjusted to 1 M
sucrose in HOMO buffer and layered on 1.2 M sucrose in HOMO buffer. HOMOA buffer was applied on the top of the gradient. The crude synaptosomal fractions
were collected at the 1 M/1.2 M interface after centrifugation for 2 h at 100,000g
and combined. The crude synaptosomal fraction was again adjusted to 1 M sucrose
and layered on the top of the 1.2 M sucrose. HOMO-A buffer was applied on the
top of the gradient. After centrifugation for 2 h at 100,000g, synaptosomes were
collected at the 1 M/1.2 M interface, resuspended in HOMO-A buffer, pulled down
by centrifugation for 30 min at 100,000g and resuspended in HOMO-A buffer.
Mice. Extraction of brain tissues from mice was approved by the Animal Care and
Ethics Committee of the University of New South Wales (permit 12/135B). Brain
tissues from one- to three-day-old wild-type C57BL/6J mice (Australian BioResources (Moss Vale, NSW, Australia)) of either sex were used for cell culture
preparation. APP23 mice express human APP under control of the murine Thy1
promoter and were as described28. The breeding colony of APP23 mice was
maintained in the Biological Resources Center at the University of New South
Wales. Brain tissue from wild-type and APP23 transgenic littermates of different
ages (as indicated in the text) and either sex were used for biochemical
experiments.
Cultures of hippocampal and cortical neurons. Cultures of hippocampal and
cortical neurons were prepared as described27,44. Neurons were maintained in
Neurobasal A medium supplemented with 2% B-27, Glutamax and 2 ng ml  1
bFGF-2 (all reagents from Life Technology) on glass coverslips coated with poly-Dlysine (100 mg ml  1, Sigma). When indicated neurons were treated for 24 h with
0.5 mM of Ab1–42 peptide (AbcamBiochemicals, Cambridge, UK) in the form of
Ab-derived diffusible ligand prepared as described previously13,47,48, and
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monoclonal antibodies against the extracellular domain of NCAM2 (2.5 mg ml  1;
R&D systems), or recombinant extracellular domains of NCAM2 (2.5 mg ml  1)
applied in the cell culture medium.
Immunoﬂuorescence labelling of cultured neurons. Indirect immunoﬂuorescence labelling was performed essentially as described previously1. Unless
otherwise stated, all steps were performed at room temperature. Neurons on glass
coverslips were ﬁxed in 4% formaldehyde in phosphate-buffered saline (PBS) for
15 min, and then washed three times with PBS. We have shown previously that this
procedure does not affect the integrity of cell surface membranes1. To label cell
surface AMPA and NMDA receptors, neurons were then blocked in 1% BSA in
PBS for 20 min. Antibodies against extracellular epitopes of GluR1 or NR1 (in 0.1%
BSA in PBS) were applied to ﬁxed but non-permeabilized cells for 1 h and detected
with ﬂuorochrome-coupled secondary antibodies applied for 45 min. The neurons
were then post-ﬁxed for 5 min in 2% formaldehyde in PBS and washed three times
with PBS. To label other proteins indicated in the text, neurons were permeabilized
with 0.25% Triton X-100 in PBS for 5 min, blocked with 1% BSA in PBS for 20 min,
and incubated with respective primary antibodies applied in 0.1% BSA in PBS
overnight at 4 °C. Neurons were then washed in PBS and incubated with
corresponding ﬂuorochrome-conjugated secondary antibodies applied for 45 min
in 0.1% BSA in PBS at room temperature. When indicated, neurons were then colabelled with Alexa Fluor 546-coupled phalloidin (Life Technologies) applied for
30 min in 0.1% BSA in PBS at room temperature. Cells were washed four times
with PBS and embedded in Aqua-Poly/Mount (Polysciences, Eppelheim,
Germany). Immunoﬂuorescence images were acquired at room temperature using
a confocal laser scanning microscope C1si, NIS Elements software and oil Plan Apo
VC  60 objective (numerical aperture 1.4), all from Nikon Corporation (Tokyo,
Japan). Numbers of synaptic and non-synaptic clusters of AMPA and NMDA
receptors were quantiﬁed in ImageJ (National Institutes of Health, USA). Clusters
were automatically outlined using a threshold function of ImageJ, and clusters in
which at least one pixel overlapped with a synaptophysin accumulation were
counted as synaptic. Length and area of dendrites were measured in ImageJ by
automatically outlining phalloidin-labelled dendrites using the threshold function
of ImageJ.
Immunoﬂuorescence labelling of mouse brain slices. Immunoﬂuoresecence
staining was done as previously described49. Brieﬂy, 9-month-old male wild-type
and APP23 mice were anaesthetized and transcardially perfused with PBS followed
by 4% paraformaldehyde in PBS. Brains were extracted and ﬁxed in 4%
paraformaldehyde/PBS overnight at 4 °C. Brains were then processed in a Excelsior
tissue processor (Thermo), embedded in parafﬁn, cut into 3-mm thick sections and
slide mounted. Sections were dewaxed, rehydrated to water and underwent heatmediated antigen retrieval with citrate buffer pH6.0 using a microwave vacuum
histoprocessor (Milestone). Nonspeciﬁc binding sites were blocked in a solution of
PBS with 3% normal horse serum and 2% BSA, and then incubated in a cocktail of
mouse monoclonal antibodies against Ab (1:100), goat polyclonal antibodies
against NCAM2 (1:50) and rabbit polyclonal antibodies against synaptophysin
(1:100) at 4 °C overnight. Sections were rinsed four times in PBS and incubated in a
cocktail of ﬂuorescent secondary antibodies (donkey anti-mouse Cy5, donkey antigoat Alexa 555, donkey anti-rabbit Cy2, 1:250) and DAPI (1:3,000) at room
temperature for 1 h. Following incubation, sections were rinsed four times in PBS,
coverslipped with Prolong gold anti-fade reagent (Life Technologies) and sealed
with nail polish. Images were acquired using a confocal laser scanning microscope
C1si, NIS Elements software and oil Plan Apo  10 (numerical aperture 1.4) and
Plan Apo VC  60 objective (numerical aperture 1.4), all from Nikon Corporation
(Tokyo, Japan).
Proximity ligation assay. Proximity ligation experiments were performed
essentially as described previously44,50. Cultured neurons were ﬁxed in 4%
formaldehyde in PBS, washed with PBS and blocked with 1% BSA in PBS for
20 min. Antibodies against the extracellular domain of NCAM2 and Ab were
applied to the cells in 0.1% BSA in PBS overnight at 4 °C. Further steps were
performed using secondary antibodies conjugated with oligonucleotides (PLA
probes, Olink Bioscience, Uppsala, Sweden) and Duolink II ﬂuorescence kit (Olink
Bioscience) in accordance with the manufacturer’s instructions. Fluorescence
images were acquired at room temperature using a confocal laser scanning
microscope Nikon C1si, NIS Elements software and oil Plan Apo VC  60
objective (numerical aperture 1.4), all from Nikon Corporation (Tokyo, Japan).
Fluorescence intensities of PL products, and synaptophysin and Ab1-42 labelling
along neurites and in neurite-free areas were measured in ImageJ.
Co-immunoprecipitation. Samples containing 1 mg of total protein were lysed
with lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na4P2O7, 1 mM
NaF, 2 mM Na3VO4, 1% (v/v) Triton X-100, 1 mM PMSF, EDTA-free protease
inhibitor cocktail (Roche)) for 1 h at room temperature. Lysates were centrifuged
for 15 min at 20,000g at 4 °C. Supernatants were cleared with protein A/G-agarose
beads (Santa Cruz Biotechnology) for 3 h, and beads were removed by centrifugation at 600g for 5 min. The supernatant was incubated with the mouse
monoclonal antibodies against the extracellular domain of NCAM2 or non16

immune mouse IgG overnight, followed by precipitation with protein A/G-agarose
beads for 3 h. The beads were pelleted and washed four times with the lysis buffer
and three times with TBS. All steps were carried out at 4 °C. The proteins were
ﬁnally eluted from beads with 5  SDS sample buffer (310 mM Tris-HCl, pH 6.8,
25% (v/v) glycerol, 10% (w/v) SDS, 4.5% (v/v) b-mercaptoethanol, 0.015% (w/v)
bromophenol blue) by incubating samples at 70 °C for 10 min and analysed by
western blot. To eliminate detection of the bands corresponding to the light chains
of the immunoglobulins used for immunoprecipitation, biotin-coupled secondary
antibodies speciﬁc to Fc fragments of the primary antibodies (Sigma) were used.
Signals were developed using NeutrAvidin-HRP protein conjugate (Pierce).
Homogenates and synaptosomes from cultured neurons. Neurons maintained
in culture for 20 days and treated as indicated in the text were placed on ice and
washed two times with ice-cold PBS. Neurons were then scrapped in 200 ml of
HOMO-A buffer and homogenized using a Potter homogenizer. Synaptosomes
were prepared as described previously26,51. Brieﬂy, the homogenate was centrifuged
for 10 min at 700g. The supernatant was collected and centrifuged at 15,000g for
15 min. The pellet was then resuspended in 5 volumes of 0.1 M K2-tartrate (pH 7.3)
and centrifuged at 5,000g for 5 min. The pellet collected, resuspended again in 5
volumes of 0.1 M K2-tartrate (pH 7.3) and centrifuged at 5,000g for 5 min. The
pellet containing synaptosomes was resuspended in HOMO-A buffer.
Analysis of proteolytic products of NCAM2 in culture medium. Media from
neurons maintained in culture for 20 days and treated as indicated was collected
and centrifuged at 200,000g for 1 h at 4 °C. The supernatant was then collected,
diluted with the same volume of 20% trichloroacetic acid, and incubated for 30 min
on ice to precipitate proteins. Precipitates were washed twice with ice-cold acetone
and used for western blot analysis.
Enzyme-linked immunosorbent assay (ELISA). To immobilize recombinant
extracellular domains of NCAM2, the plastic surface of MaxiSorp 96-well plates
(Nunc, Roskilde, Denmark) was coated with antibodies against the extracellular
domain of NCAM2 (10 mg per well) applied overnight at 4 °C in PBS. Wells were
then washed three times with PBS containing 0.05% Tween 20, blocked with 1%
BSA in PBS for 1 h at room temperature, and incubated overnight at 4 °C with
recombinant extracellular domains of NCAM2 (25 nM) or BSA (25 nM) in PBS
containing 0.05% Tween 20 and 0.1% BSA. Wells were washed three times with
PBS containing 0.05% Tween 20 and incubated with different concentrations of
Ab1-42 (7.8–250 nM) diluted with 0.05% Tween 20 and 0.1% BSA. Wells were
washed three times with PBS containing 0.05% Tween 20. Ab1-42 bound to
NCAM2 was detected with antibodies against Ab1-42 followed by HRP-conjugated
secondary antibodies. Protein binding was visualized by detecting HRP with the
OPD reagent (Pierce, Rockford, IL, USA) that resulted in a coloured product. The
amount of coloured product was quantiﬁed using an ELISA reader at 406 nm.
Dynamic light scattering. Dynamic light scattering (DLS) measurements were
performed at room temperature using Zetasizer Nano ZS (Malvern, Malvern, UK)
in accordance with the manufacturer’s instructions.
Production of the extracellular domains of NCAM2. DNA coding for the
extracellular domain of mouse NCAM2 (amino acids 1–698) was ampliﬁed from
the mouse brain cDNA library using forward 50 -CACCATGAGCCTCCTCCT
CTCCTTCTACC-30 and reverse 50 -TTCGCTTCACAGCAATTATCTTTAATAA
TGTTGGGTTTT-30 primers, cloned into pEF5/FRT/V5 directional expression
vector (Life Technologies) and transfected into CHO cells (American Type Culture
Collection, CHO-K1, ATCC CCL-61). Cells stably transfected with the construct
were selected with Hygromycin B (Life Technology) and maintained in culture in
Ham’s F-12 culture medium (PAA Laboratories) with 5% foetal bovine serum (Life
Technologies). Cell culture media containing the extracelluar domain of NCAM2
secreted by the cells was collected and centrifuged for 15 min at 5,000g at 4 °C to
remove cell debris. The protein was concentrated with 40% ammonia sulphate,
desalted and puriﬁed using a continuous-elution electrophoresis cell (Model 491
Prep Cell, Bio-Rad) according to the manufacturer’s instructions. The purity of the
protein was controlled by SDS–PAGE electrophoresis with subsequent silver
staining and western blot analysis.
Peptide cleavage assay. Hippocampal tissue or synaptosomes containing 1 mg of
total protein were lysed with lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1 mM Na4P2O7, 1 mM NaF, 1% (v/v) Triton X-100, protease inhibitor cocktail (set
III, Merck)) for 30 min at room temperature. Lysates were centrifuged for 15 min at
20,000g at 4 °C. Peptides corresponding to amino acids 682–701 (NCAM2aa682701) and 666-685 (NCAM2aa666-685) of human NCAM2, and mutated NCAM2aa682-701 peptides with aspartic acid 693 exchanged to alanine or asparagine
689 exchanged to alanine were purchased from Peptide 2.0 (Chantilly, VA, USA).
The peptides contained FITC and biotin at the N- and C-termini, respectively.
Peptides (250 ng ml  1 ﬁnal concentration) were mixed with lysates of hippocampal tissue or synaptosomes (20 mg of total protein in 1 ml of TBS) and
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incubated for 1 h at room temperature. Non-cleaved peptides and biotin-containing fragments of cleaved peptide were removed by incubating lysates with
hydrophilic streptavidin magnetic beads (New England BioLabs) for 1 h at room
temperature. Fluorescence of FITC groups attached to fragments of cleaved peptides remaining in the solution was measured using POLARstar Omega plate
reader (BMG Labtech).
Transfection of neurons. The NCAM2 miR expression vector was developed
using the BLOCK-iT PolII miR RNAi expression vector kit (Life Technologies) and
designed to co-express NCAM2-speciﬁc miRNA together with emerald GFP. The
following oligonucleotides were inserted into the BLOCK-iT PolII miR RNAi
expression vector:
top: 50 -TGC TGT TAA GGT CAT CTC TTC TCC TCG TTT TGG CCA CTG
ACT GAC GAG GAG AAG ATG ACC TTA A-30 ;
bottom: 50 -CCT GTT AAG GTC ATC TTC TCC TCG TCA GTC AGT GGC
CAA AAC GAG GAG AAG AGA TGA CCT TAA C-30 .
Negative control miR vector was from Life Technologies. Immunocytochemical
labelling conﬁrmed that transfection with the NCAM2 miR vector resulted in an
over 80% reduction in expression of NCAM2 in cultured hippocampal neurons at
24 h after transfection (Supplementary Fig. 5).
DNA coding for the full-length transmembrane human NCAM2 and NCAM2
with aspartic acid 693 exchanged to alanine (NCAM2D693A mutant) was
synthesized using the GeneArt Gene Synthesis service (Life Technologies) and
subcloned into the pcDNA3 vector. Both constructs contained an HA tag inserted
at the N-terminus of the protein. The expression of both constructs was conﬁrmed
by western blot and immunocytochemistry (Supplementary Fig. 2).
Hippocampal neurons were transfected before plating by electroporation using
the Neon transfection system (Life Technologies).
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